BR112021024151A2 - Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho - Google Patents

Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho

Info

Publication number
BR112021024151A2
BR112021024151A2 BR112021024151A BR112021024151A BR112021024151A2 BR 112021024151 A2 BR112021024151 A2 BR 112021024151A2 BR 112021024151 A BR112021024151 A BR 112021024151A BR 112021024151 A BR112021024151 A BR 112021024151A BR 112021024151 A2 BR112021024151 A2 BR 112021024151A2
Authority
BR
Brazil
Prior art keywords
eye
protein aggregation
pharmacological agents
treating
aggregation diseases
Prior art date
Application number
BR112021024151A
Other languages
English (en)
Portuguese (pt)
Inventor
Clarke Peterman Marshall
Santosh Sinha
Govinda Prasad Sridhar
Original Assignee
Plex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plex Pharmaceuticals Inc filed Critical Plex Pharmaceuticals Inc
Publication of BR112021024151A2 publication Critical patent/BR112021024151A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021024151A 2019-05-31 2020-06-01 Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho BR112021024151A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855560P 2019-05-31 2019-05-31
PCT/US2020/035592 WO2020243720A1 (en) 2019-05-31 2020-06-01 Pharmacological agents for treating protein aggregation diseases of the eye

Publications (1)

Publication Number Publication Date
BR112021024151A2 true BR112021024151A2 (pt) 2022-02-08

Family

ID=73553335

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024151A BR112021024151A2 (pt) 2019-05-31 2020-06-01 Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho

Country Status (8)

Country Link
US (1) US20220241247A1 (enExample)
EP (1) EP3976017A4 (enExample)
JP (1) JP2022534420A (enExample)
CN (1) CN114173771A (enExample)
BR (1) BR112021024151A2 (enExample)
CA (1) CA3141998A1 (enExample)
MX (1) MX2021014682A (enExample)
WO (1) WO2020243720A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512116A (ja) * 2020-01-28 2023-03-23 プロテゴ バイオファーマ， インコーポレイテッド トランスサイレチンの安定化及びトランスサイレチンの誤った折り畳みの阻害のための化合物、組成物、及び方法
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
WO2023278604A1 (en) * 2021-06-29 2023-01-05 Plex Pharmaceuticals, Inc. Pharmacological agents for treating ophthalmic diseases
WO2023009585A2 (en) * 2021-07-28 2023-02-02 Protego Biopharma, Inc. Transthyretin stabilizing compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112913A1 (en) * 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
WO2013038351A1 (en) * 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
JP6068484B2 (ja) * 2011-10-24 2017-01-25 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法
US9499527B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
JP2016514091A (ja) * 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
BR112015021836A2 (pt) * 2013-03-08 2017-07-18 Allergan Inc conjugados de antibióticos diretamente ligados com drogas esteroides
US9789091B2 (en) * 2013-03-14 2017-10-17 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
US11872236B2 (en) * 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Also Published As

Publication number Publication date
WO2020243720A9 (en) 2021-02-04
MX2021014682A (es) 2022-04-06
EP3976017A4 (en) 2023-06-14
WO2020243720A1 (en) 2020-12-03
US20220241247A1 (en) 2022-08-04
JP2022534420A (ja) 2022-07-29
CN114173771A (zh) 2022-03-11
CA3141998A1 (en) 2020-12-03
EP3976017A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
BR112021021230A8 (pt) Forma de cristal de composto inibidor de wee1 e uso do mesmo
BR112017024934A2 (pt) composições farmacêuticas tópicas
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112023002553A2 (pt) Composto, composição, uso do composto e uso da composição
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112022002630A2 (pt) Composição farmacêutica em pó seco adequada para administração por inalação, inalador de pó seco e método de tratamento ou prevenção de doenças ou condições
MX2021014682A (es) Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022025946A2 (pt) Composto, composição farmacêutica e método de tratamento de uma doença
BR112022026999A2 (pt) Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
BR112021015744A2 (pt) Combinações de compostos de beta-lactama e probenecida e seu uso
BR112022001395A2 (pt) Métodos para administrar anticorpos anti-siglec-8 e corticosteroides
BR112021024109A2 (pt) Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
EA202190966A1 (ru) Пролекарства антагонистов cgrp
BR112022015800A2 (pt) Tratamento de colangite biliar primária com elafibranor
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112012022052A2 (pt) método para o tratamento ou prevenção de sintomas da variação hormonal, composição farmacêutica para o tratamento ou prevenção de sintomas da variação hormonal e kit para o tratamento ou prevenção de sintomas da variação hormonal
Ganekal et al. Effect of topical calcium channel blockers on intraocular pressure in steroid-induced glaucoma
BR112023025221A2 (pt) Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos
Zhou et al. Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements